Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on harnessing the potential of hypoxia-inducible factor (HIF)
biology to develop and commercialize novel therapeutics to treat kidney
disease, today announced that Michael D.
for - Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors investment picks